TIDMERGO

RNS Number : 8031U

Ergomed plc

16 July 2018

PRESS RELEASE

16 July 2018

Notification re Change of Auditors

Ergomed plc ("Ergomed" or the "Company")

At the Company's Annual General Meeting held on 12 June 2018, a resolution to appoint KPMG as Ergomed's auditors was proposed and approved by shareholders.

Ergomed now announces that on 13 July 2018 it wrote to shareholders explaining that, as planned, Deloitte LLP had resigned as auditor and KPMG had been appointed as the Company's new auditor. And as required by the Companies Act the Company also sent to shareholders a statement of Deloitte's reasons for their ceasing to hold office (namely that the directors of Ergomed have decided to appoint another firm as auditors).

This announcement is being made pursuant to the requirements of AIM Rule 20.

Enquiries:

 
 Ergomed plc                                        Tel: +44 (0) 1483 503 
                                                                      205 
 Stuart Jackson (Chief Financial Officer) 
 
 Numis Securities Limited                            Tel: +44 (0) 20 7260 
                                                                     1000 
 Michael Meade / Freddie Barnfield (Nominated 
  Adviser) 
 James Black (Joint Broker) 
 
 N+1 Singer                                          Tel: +44 (0) 20 7496 
                                                                     3000 
 Aubrey Powell (Joint Broker) 
 
 Consilium Strategic Communications                  Tel: +44 (0) 20 3709 
  - for UK enquiries                                                 5700 
 Chris Gardner / Mary-Jane Elliott            ergomed@consilium-comms.com 
  Ivar Milligan / Olivia Manser 
 
 MC Services - for Continental European            Tel: +49 211 5292 5222 
  enquiries 
 Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCEAKXKFAXPEFF

(END) Dow Jones Newswires

July 16, 2018 12:31 ET (16:31 GMT)

Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ergomed Charts.
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ergomed Charts.